Clinical Scorecard: Injectable Targets Décolleté Wrinkles

At a Glance

Key Highlights

• RADIESSE dermal filler approved by FDA for décolleté wrinkle treatment in patients 22+ years
• Effects last up to 2 years by enhancing dermal integrity through collagen and elastin production
• High patient satisfaction with over 80% reporting improved skin tightness and interest in repeat treatments

Guideline-Based Recommendations

Diagnosis

• Assessment of wrinkles and skin laxity in the décolleté area suitable for injectable treatment

Management

• Use RADIESSE dermal filler as a biostimulator to improve skin firmness and smoothness
• Avoid use in patients with allergies to product components, severe allergic reaction history, or bleeding disorders
• Do not use in anatomical areas where safety is not established, such as lips and periorbital region

Monitoring & Follow-up

• Monitor for adverse events including bruising, redness, swelling, pain, itching, difficulty chewing, and nodules
• Be vigilant for signs of unintentional intravascular injection which may cause vision abnormalities or stroke

Risks

• Potential adverse events at injection site including bruising and nodules
• Serious complications from intravascular injection such as vision abnormalities and stroke
• Contraindicated in pregnant or breastfeeding patients and those under 22 years for décolleté indication

Patient & Prescribing Data

Patients aged 22 years and older seeking treatment for décolleté wrinkles

More than 80% patient satisfaction with skin tightness; 83% likely to repeat treatment after 1 year; 93% interested in additional treatments

Clinical Best Practices

• Confirm patient eligibility including age and absence of contraindications before treatment
• Educate patients on expected outcomes and potential adverse events
• Use proper injection techniques to minimize risk of intravascular injection
• Schedule follow-up to assess treatment efficacy and monitor for adverse effects

Related Resources & Content

• Merz Aesthetics Press Release